Apogee Therapeutics, Inc.

NasdaqGM APGE

Apogee Therapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 450.54 M

Apogee Therapeutics, Inc. Net Cash Used Provided By Financing Activities is USD 450.54 M for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
NasdaqGM: APGE

Apogee Therapeutics, Inc.

CEO Dr. Michael Thomas Henderson M.D.
IPO Date July 14, 2023
Location United States
Headquarters 221 Crescent Street
Employees 91
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email